Corona and Parley for the Oceans partner with Stephanie Gilmore, Gabriel Medina and artists to support the ban of single-use plastic in Bali and provide households with reusable alternatives.
14.5.2019 10:00:00 EEST | Business Wire | Press release
It is estimated that roughly 5 trillion plastic bags are consumed worldwide each year1 with as many as 10 million plastic bags entering circulation in Indonesia every day2. Earlier this year, Bali announced a ban of all single-use plastic (including plastic bags) that takes affect later this year. For the first time, Balinese would have to rely on reusable bags exclusively.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005361/en/
Corona's La Casa pop-up space, made from 1.5 tons of recycled plastic. (Photo: Business Wire)
To help support the local NGOs who have been leading the charge against single-use plastic and as part of their commitment to the region where the annual Bali Pro-tected surf event takes place, Corona, Parley and World Surf League are donating 20,000 reusable bags made from Ocean Plastic®. Limited edition bags are also being created on-site and will be sold in real-time at wslstore.com. The proceeds from each bag purchased funds the donation of an additional 3 bags to the local community and the removal of more than 20 bottles worth of plastic. The ambition over time is to provide one bag for every household in Indonesia.
The limited-edition bags were designed by Stephanie Gilmore, Gabriel Medina and Rosy Hodge in partnership with artists Nadia Hernandez, Speto and Gemma O’Brien respectively. Surfers on the WSL Championship Tour have also shown their support by designing their own bags to raise awareness of the project. The collaborators are part of the inaugural “La Casa” pop-up, a house made from 1.5 tons of recycled plastic in partnership with NevHouse. Founded by Corona, the house will become a platform for surfers, artists and thought-leaders to work on projects that can inspire a better world. The house itself is a positive reminder that plastic can be given a meaningful second life, much like the bags. Each pop-up will include new collaborators and new projects to help protect paradise from plastic pollution.
“The La Casa platform is about collaboration and creativity to energize the fight against marine plastic pollution,” said Evan Ellman, Corona Better World Director. “In this case, Corona and our partners Parley and World Surf League, were inspired by the movement to ban single-use plastic in Bali and recognized an opportunity to support the transition. Just as impressive are the talented collaborators who signed on to bring their voice and point of view to the project. The result is a product that is not only a symbol of change, but also has a significant impact on the environment and community.”
La Casa is the latest initiative from Corona and Parley for the Oceans who have a mutual mission to protect the world’s oceans and beaches. To date, the partnership has engaged in 100 islands around the world through a clean-up network present in over 23 countries, resulting in 537 clean-ups, 25,000 volunteers and more than 3 million square meters of beach cleaned. This includes Corona’s support of Parley’s strategy to end marine plastic pollution: A.I.R. (Avoid, Intercept and Redesign). Most recently, Corona and Parley partnered with Oscar-nominated stop-motion artist PES to create a film on Earth Day raising awareness that “avoiding” and “intercepting” plastic saves the lives of marine wildlife. The La Casa initiative in Bali is an example of how that plastic can be “redesigned” into a product that replaces single-use plastic.
La Casa Corona will be at the Corona Bali Pro-tected event in Keramas, Bali, Indonesia from May 13 - May 25, 2019. To learn more and purchase a bag visit wslstore.com.
-###-
ABOUT CORONA
Born in Mexico, Corona is the leading beer brand in the country, the most popular Mexican beer worldwide exported to more than 180 countries. Corona Extra was first brewed in 1925 at the Cervecería Modelo in Mexico City. Corona is a pioneer in the beer industry by being the first to use a transparent bottle showcasing its purity and high quality to the world. The artwork found on the bottle is painted, highlighting our commitment to quality in our packaging and our Mexican heritage. No Corona is complete without the lime. Naturally adding character, flavor and refreshment, the lime ritual is an integral part of delivering an experience that is truly unique to Corona. The brand is synonymous with the beach and celebrates time outdoors. It invites people to pause, relax and enjoy the simple pleasures of life.
ABOUT PARLEY FOR THE OCEANS
Parley for the Oceans is the global network where creators, thinkers and leaders from the creative industries, brands, governments and environmental groups come together to raise awareness for the beauty and fragility of the oceans and collaborate on projects that can end their destruction. The organization has formed alliances with major corporations including adidas, Anheuser Busch InBev (Corona), American Express; the United Nations; the Maldives and collaborators spanning the worlds of science, art, fashion, design, entertainment, sports, and space and ocean exploration. To know more: www.parley.tv
ABOUT THE WSL
The World Surf League (WSL) is the global home of surfing, dedicated to celebrating the world's best surfing on the world's best waves. The WSL has been championing the world's best surfing since 1976, annually running more than 180 global events across the Men's and Women's Championship Tours, the Big Wave Tour, the Longboard Tour, Qualifying Series, Pro Junior Tour, as well as the WSL Big Wave Awards. The League possesses a deep appreciation for the sport's rich heritage while promoting progression, innovation, and performance at the highest levels, and in doing so crowns the undisputed Men’s and Women’s World Champions across all tours. For more information, please visit WorldSurfLeague.com.
1
https://wedocs.unep.org/bitstream/handle/20.500.11822/25513/state_plastics_WED.pdf?isAllowed=y&sequence=1
2
https://www.theinertia.com/environment/indonesia-pledges-1-billion-a-year-to-reduce-its-ocean-waste/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005361/en/
Contact information
Alison Brod Marketing + Communications:
Corona@alisonbrodmc.com
212-230-1800
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
